Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: an overview
D Fedele, A De Francesco, S Riso, A Collo - Nutrition, 2021 - Elsevier
The world is currently facing the coronavirus disease (COVID-19) pandemic which places
great pressure on health care systems and workers, often presents with severe clinical …
great pressure on health care systems and workers, often presents with severe clinical …
[HTML][HTML] Antivirals for COVID-19: a critical review
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as
the development of antivirals usually requires time. Therefore, assessment and use of …
the development of antivirals usually requires time. Therefore, assessment and use of …
Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6
W Niu, F Wu, W Cao, Z Wu, YC Chao, F Peng… - Bioscience …, 2021 - portlandpress.com
Objective:´ Three formulas and three medicines,'namely, Jinhua Qinggan Granule, Lianhua
Qingwen Capsule, Xuebijing Injection, Qingfei Paidu Decoction, HuaShi BaiDu Formula …
Qingwen Capsule, Xuebijing Injection, Qingfei Paidu Decoction, HuaShi BaiDu Formula …
Antimicrobial photodynamic therapy in the control of COVID-19
A Almeida, MAF Faustino, MG Neves - Antibiotics, 2020 - mdpi.com
Antimicrobial photodynamic therapy (aPDT), using well known, safe and cost-effective
photosensitizers, such as phenothiazines, eg, methylene blue (MB), or porphyrins, eg …
photosensitizers, such as phenothiazines, eg, methylene blue (MB), or porphyrins, eg …
Biocatalytic routes to anti-viral agents and their synthetic intermediates
S Slagman, WD Fessner - Chemical Society Reviews, 2021 - pubs.rsc.org
With recent outbreaks of COVID-19 and Ebola, health and healthcare have once more
shown to be heavily burdened by the lack of generally effective anti-viral therapies. Initial …
shown to be heavily burdened by the lack of generally effective anti-viral therapies. Initial …
Opportunities for biomaterials to address the challenges of COVID‐19
Abstract The coronavirus disease 2019 (COVID‐19) pandemic has revealed major
shortcomings in our ability to mitigate transmission of infectious viral disease and provide …
shortcomings in our ability to mitigate transmission of infectious viral disease and provide …
Care for patients with stroke during the COVID-19 pandemic: physical therapy and rehabilitation suggestions for preventing secondary stroke
CC Wang, JK Chao, ML Wang, YP Yang… - Journal of Stroke and …, 2020 - Elsevier
Infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
causes the development of the novel 2019 coronavirus disease (COVID-19) and associated …
causes the development of the novel 2019 coronavirus disease (COVID-19) and associated …
Antioxidant, anti-inflammatory, and immunomodulatory roles of nonvitamin antioxidants in anti-SARS-CoV-2 therapy
AM Pisoschi, F Iordache, L Stanca… - Journal of Medicinal …, 2022 - ACS Publications
Viral pathologies encompass activation of pro-oxidative pathways and inflammatory burst.
Alleviating overproduction of reactive oxygen species and cytokine storm in COVID-19 is …
Alleviating overproduction of reactive oxygen species and cytokine storm in COVID-19 is …
Vaccines and therapies in development for SARS-CoV-2 infections
D Wu, R Koganti, UP Lambe, T Yadavalli… - Journal of clinical …, 2020 - mdpi.com
The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus
causes severe respiratory symptoms which manifest disproportionately in the elderly …
causes severe respiratory symptoms which manifest disproportionately in the elderly …
[HTML][HTML] Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19
U Norinder, A Tuck, K Norgren, VM Kos - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Given the speed of viral infection spread, repurposing of existing drugs has been given the
highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already …
highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already …